Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Next Generation Sequencing: Research to Clinic

Charles Cantor's Biography

Charles Cantor, Chief Scientific Officer, Sequenom Inc

Charles Cantor is a founder, and Chief Scientific Officer at SEQUENOM, Inc. He is also founder of SelectX Pharmaceuticals, a drug discovery company based in the Boston area; Retrotope, an anti-aging company; and DiThera, a biotherapeutic company. He is co-director of the Center for Advanced Biotechnology at Boston University, and professor emeritus of Biomedical Engineering. Dr. Cantor has held positions at Columbia University and University of California at Berkeley, and was also director of the Human Genome Center of the Department of Energy at Lawrence Berkeley Laboratory. He has published more than 450 peer-reviewed articles, has been granted more than 60 patents. He co-authored a three-volume textbook on Biophysical Chemistry and the first textbook on Genomics: The Science and Technology of the Human Genome Project. He sits on the advisory boards of more than 15 national and international organizations and is a member of the National Academy of Sciences.

Charles Cantor Image

Noninvasive Personalized Genomics

Tuesday, 25 February 2014 at 13:45

Add to Calendar ▼2014-02-25 13:45:002014-02-25 14:45:00Europe/LondonNoninvasive Personalized GenomicsNext Generation Sequencing: Research to Clinic in San Diego, California, USASan Diego, California,

Most of the DNA in blood is contained in nucleated white blood cells. But a small amount of circulating DNA arises from distant locations. Most of this is short free DNA fragments produced by apoptosis. If these fragments have DNA sequence or epigenetic differences from the free DNA that arises from white blood cell death or breakage, characterization of the differences allows information to be obtained about remote sites in the body where apoptosis has occurred. Noninvasive prenatal testing based on circulating free fetal DNA fragments is a mature commercial endeavor. DNA sequencing is used to detect aneuplodies but more focused assays can also be employed to look at specific loci. In 2013 more than half a million women were tested noninvasively by plasma DNA sequencing.  It is reasonable to expect that a similar analysis of circulating cancer DNA will be extremely useful clinically but these applications are still in their infancy. In cancer the need to monitor a patient’s plasma DNA frequently strains the abilities and throughputs of current sequencing platforms. Future applications are likely to be developed wherever apoptosis produces clinically useful circulating DNA fragments.

Add to Calendar ▼2014-02-24 00:00:002014-02-25 00:00:00Europe/LondonNext Generation Sequencing: Research to ClinicNext Generation Sequencing: Research to Clinic in San Diego, California, USASan Diego, California,